Deprescribing Tool for Older PeoPle with Limited-life Expectancy (De-TOPPLE) version 1: Development and validation using a modified Delphi technique

被引:2
|
作者
Shrestha, Shakti [1 ,4 ]
Poudel, Arjun [2 ]
Steadman, Kathryn J. [1 ]
Nissen, Lisa M. [3 ]
机构
[1] Univ Queensland, Sch Pharm, Brisbane, Qld, Australia
[2] Queensland Univ Technol, Sch Clin Sci, Brisbane, Qld, Australia
[3] Univ Queensland, Ctr Business & Econ Hlth, Brisbane, Qld, Australia
[4] Univ Queensland, Pharm Australia Ctr Excellence, Sch Pharm, 20 Cornwall St, Woolloongabba, Qld 4102, Australia
关键词
consensus; Delphi; deprescribing; frail; older adults; terminal illness; validation; END; ADULTS;
D O I
10.1111/bcpt.13907
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Deprescribing decision making in older adults with limited life expectancy is often challenging for clinicians. We aimed to develop and validate a Deprescribing Tool for Older People with Limited-life Expectancy (De-TOPPLE). Modified Delphi technique was used to gain experts' consensus on the tool and further develop using their feedback. Experts [Round-1 (n = 13), Round-2 (n = 7)] had clinical and/or research background on geriatric medicine, geriatrics, family medicine or pharmacotherapy. Round-1 consensus was achieved on approach taken by the tool to evaluate risk and benefit; distinguishing medications as preventive, symptom control or dual-purpose; referring to established deprescribing process; stepwise approach to deprescribing; and the overall concept. Common feedback was to reflect upon harm-benefit analysis, distinguish medication types earlier, qualify adverse events, use time-to-benefit (TTB), prioritise symptom relief, monitor post-deprescribing, include shared decision making and define terms for clinical familiarisation. After tool update, Round-2 consensus was achieved on usability in clinical setting, flexibility of implicit judgement, ceasing preventive medication with inadequate TTB, ceasing symptom control medication with inadequate symptom relief, ceasing dual-purpose medication (DPM) with inadequate TTB and symptom relief, and continuing DPM with adequate TTB and symptom relief. De-TOPPLE version 1 was developed and validated through two rounds of the Delphi process. Clinical use of the tool needs final validation following the addition of contextual statements to the tool.
引用
收藏
页码:15 / 27
页数:13
相关论文
共 4 条
  • [1] Deprescribing tool for use in older Australians with life-limiting illnesses and limited life expectancy: a modified-Delphi study protocol
    Shrestha, Shakti
    Poudel, Arjun
    Steadman, Kathryn J.
    Nissen, Lisa M.
    BMJ OPEN, 2021, 11 (04):
  • [2] Translation, cross-cultural adaptation, and validation of the Danish version of the revised Patients' Attitudes Towards Deprescribing (rPATD) questionnaire: Version for older people with limited life expectancy
    Lundby, Carina
    Simonsen, Trine
    Ryg, Jesper
    Sondergaard, Jens
    Pottegard, Anton
    Lauridsen, Henrik Hein
    RESEARCH IN SOCIAL & ADMINISTRATIVE PHARMACY, 2021, 17 (08) : 1444 - 1452
  • [3] Development and validation of a tool to understand health care professionals' attitudes towards deprescribing (HATD) in older adults with limited life expectancy
    Shrestha, Shakti
    Poudel, Arjun
    Reeve, Emily
    Linsky, Amy M.
    Steadman, Kathryn J.
    Nissen, Lisa M.
    RESEARCH IN SOCIAL & ADMINISTRATIVE PHARMACY, 2022, 18 (09) : 3596 - 3601
  • [4] Deprescribing in older people approaching end-of-life: development and validation of STOPPFrail version 2
    Curtin, Denis
    Gallagher, Paul
    O'Mahony, Denis
    AGE AND AGEING, 2021, 50 (02) : 465 - 471